TRAIL Receptor Antibodies
TRAIL induces apoptosis preferentially in malignant tissues. Therefore, TRAIL is considered to be a potential antineoplastic drug. Agonistic TRAIL receptor antibodies have been developed as alternative pharmacological tool for apoptosis induction via the TRAIL receptors.
After having identified TRAIL as a member of the family of cell death-inducing ligands, it became obvious that TRAIL has a strong propensity for transformed or malignant tissues. Therefore, TRAIL is considered to be a candidate anticancer drug. TRAIL exerts its apoptosis-inducing activity via the two respective agonistic TRAIL receptors DR4 and DR5. TRAIL itself is able to induce cell death in a wide array of cancer cells in vitro or when grown in xenograft settings. The efficacy of TRAIL is increased whenever the ligand is combined with conventional cytostatic agents or ionizing radiation. Depending on the production...